Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
about
Antibody-drug conjugates as novel anti-cancer chemotherapeuticsCaveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionTrastuzumab emtansine: mechanisms of action and drug resistanceNovel systemic therapy against malignant pleural mesothelioma.Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell cAnti-ABCG2 scFv antibody of lung adenocarcinoma increases chemosensitivity and induces apoptosis through the activation of mitochondrial pathway.A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells.HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.Fast and selective labeling of N-terminal cysteines at neutral pH via thiazolidino boronate formation.Site-specific antibody drug conjugates for cancer therapyMarine Antibody-Drug Conjugates: Design Strategies and Research Progress.Current ADC Linker Chemistry.Biomedical applications of trastuzumab: as a therapeutic agent and a targeting ligand.Protein trafficking in colorectal carcinogenesis-targeting and bypassing resistance to currently applied treatments.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.Use of single chain antibody derivatives for targeted drug delivery.A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence-Quencher Probe as a Tool for Functional Antibody Screening.TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticalsDropArray™, a wall-less 96-well plate for uptake and immunofluorescence microscopy, confirms CD22 recycles.Antibody-induced dimerization of FGFR1 promotes receptor endocytosis independently of its kinase activity.The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends.A novel enediyne-integrated antibody-drug conjugate shows promising anti-tumor efficacy against CD30+ lymphomas.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.Fate of Antibody-Drug Conjugates in Cancer Cells.Metal-bound claMP Tag inhibits proteolytic cleavage.Conjugates of Small Molecule Drugs with Antibodies and Other Proteins.Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective.Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells.Antibody-Drug Conjugates for Cancer Therapy.Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer
P2860
Q26800175-3AF09D00-C67B-4996-A4C0-D00EC1A439F7Q28546477-09033EAA-EA5F-436F-92A6-36CFA052BD18Q28829301-AD4451B8-9193-47D4-9EE4-1BEF632B9819Q33759627-4D9B6F7D-F7E8-40BD-9B1D-5C89BAEF4829Q33890499-3BE8E82E-98B6-4057-A49E-2CA38A1AC1A0Q33995700-652EA32F-387B-4E07-92EF-E8DECB6E693DQ36050053-E909744A-F64F-4D4A-8BB5-9B0E77532B41Q36213205-55F4D0D0-D3F1-4348-A993-5D2FE169153FQ37269081-3F0F6684-4E14-48C0-98B4-AF58D13F7036Q37546173-1AFDB4AB-A790-4E1A-BDA6-A2B63E01BDB1Q37593705-1967D568-8DCB-41E1-9196-E13BD6C1489CQ37628646-E8A0830F-0FFE-47A5-907A-CBA159B5D9B2Q38373185-F106D17F-7C04-4495-AC00-D733797E5C39Q38408138-403C9E64-27CC-4FBD-A1EB-C80183FCD18CQ38415868-C6D880CD-A3E9-461A-8025-FCAD4F9C02AEQ38489049-4C465B24-313E-4D5B-A5A6-77F6271F3D65Q38537257-C7876DFC-5371-4459-9D75-4C7FABFDDCB2Q38648690-FA715A28-844A-4C99-AE3C-3E53BB0AAB21Q38850046-1B5DF178-2167-44CF-B10E-5EF637D39778Q38869540-72BFB366-92AD-4C69-9ED2-DA1394190A88Q38920996-5BC4E077-BDC4-46F3-80CD-00AA2AF15E17Q38957698-5CC273AB-0D4E-41CE-8934-305A9975B72FQ39044402-F253E148-CFE3-4905-A161-47F4FE73A7CDQ41221244-D45EFF55-9335-43CB-A6D0-6525E494F5A2Q41280225-7116A8ED-DD89-4D62-A12C-0B7C0C230DC8Q41282870-4FA9D2D7-3B65-43F5-9D90-CDA465903A6DQ42499937-11050592-5F6E-4E87-994F-F28C5FB4BAFAQ45728543-D844E8C6-ED97-486C-8004-2E207997AC8BQ47217500-1AAA440D-4B29-467A-8145-61D51A70F973Q47661007-9F1A8A23-B9C0-448D-89AC-91D59799C16BQ47851750-8D44B526-7542-4A3E-95A7-9CBF4B20CABFQ49883378-6D52A93D-6D44-4BFB-91D4-2FAF6716773DQ50624935-38B1F164-A857-458F-894F-0C1EEC0F17C7Q50977893-99AE8008-8555-4355-9E0D-EACFA10B7CCCQ51021486-9A23E802-8D9E-4FB8-90C5-9005539269F6Q52704026-803E6E9A-FC08-43A3-9098-8AAA5EE3324FQ52729178-536AEDE6-EA15-476A-A990-58A352B4B900Q53739135-B42B78FA-8A37-4C02-9F31-C1D604E90A1BQ55347137-2260129F-A9F1-482A-9A30-268858F77BCBQ58778783-1C1F2F7A-9FB6-416C-8D35-A736BE86625E
P2860
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
description
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Implications of receptor-media ...... nt of antibody drug conjugates
@ast
Implications of receptor-media ...... nt of antibody drug conjugates
@en
Implications of receptor-media ...... nt of antibody drug conjugates
@nl
type
label
Implications of receptor-media ...... nt of antibody drug conjugates
@ast
Implications of receptor-media ...... nt of antibody drug conjugates
@en
Implications of receptor-media ...... nt of antibody drug conjugates
@nl
prefLabel
Implications of receptor-media ...... nt of antibody drug conjugates
@ast
Implications of receptor-media ...... nt of antibody drug conjugates
@en
Implications of receptor-media ...... nt of antibody drug conjugates
@nl
P2093
P2860
P921
P356
P1476
Implications of receptor-media ...... nt of antibody drug conjugates
@en
P2093
Lioudmila Tchistiakova
Michael Ritchie
Nathan Scott
P2860
P356
10.4161/MABS.22854
P407
P577
2012-12-06T00:00:00Z
2013-01-01T00:00:00Z